COMPANY

Global bio venture company specializing in cell therapy products

History

Humancellbiois leaping forward as a leading bio company representing Korea.

2018

  • Company establishment

  • Standardized Core technology for immune cell culturing completed

2020

  • Joint research MOU with CHA Univ. for cell research and storage

  • Pre-clinical trial of NK cell therapy for liver cancer

  • Patent application for method of culturing NK cells through utilizing the composition NK cell culture

  • Launched ginseng berry ODF NK JIN

  • Patent applications for PM CURE

2019

  • GMP facility completion

  • Launched immune cell extract cosmetics

  • Established R&D facility and acquired venture certification

  • SCOR (DGB/KB Bank)

  • ISO 9001/14001 Certified

2024

  • Technology transfer with Vietnam for regenerative therapy

  • GMP facility approval

  • Launched ginseng berry ODF MITO JIN

2023

  • Youth-friendly Hidden Champion certified

  • Published research results on international journal(Cancers, 2023Jun, 15(12): 3225)

  • GMP facility expansion(Songdo Techno Park IT center)

  • Permission for "human cell management business, etc.“

  • Best family friendly management

2022

  • Appointed SK Securities for IPO

  • Selected as R&D company for National Project(KFRM/1.5 billion KRW)

  • Hidden champion certified

  • 3 Patented technology transfer agreement including tendinopathy treatment using mitochondria with CHA Univ.

2021

  • Technology licensing with CHA Univ. for the method of mass culturing stem cells

  • MOU with ZTO Ltd. for overseas business